Company: BIAF
Filing Date: 2025-04-22
Form Type: 424B3
Source: 0001641172-25-005598
Chunk: 8

Company: bioAffinity Technologies, Inc.
Filing Date: 2025-04-22
Form: 424B3
Chunk 8
---
ing the adoption of these accounting standards until they would apply to private companies. We have elected to avail ourselves of
the extended transition period for complying with new or revised financial accounting standards. As a result of the accounting standards
election, we will not be subject to the same implementation timing for new or revised accounting standards as other public companies that
are not EGCs which may make comparison of our financials to those of other public companies more difficult.

Summary of Risk Factors

Like any emerging growth company, we face significant
risk factors that may impede our plans for successful commercialization of our diagnostic and therapeutic products. These risks are discussed
in detail under the “Risk Factors” discussion beginning on page 8 of this prospectus.

| 2 |

The following summarizes the principal factors that
make an investment in our Company speculative or risky, all of which are more fully described in the section below titled “Risk
Factors.” This summary should be read in conjunction with the section below titled “Risk Factors” and should not be
relied upon as an exhaustive summary of the material risks facing our business. The following factors could result in harm to our business,
reputation, revenue, financial results, and prospects, among other impacts:

Risks Related to Our Financial Position

| ● | Our business plan relies upon our ability to obtain additional sources of 
 capital and financing.                                                    |

| ● | We must raise additional capital to fund our operations in order to continue 
 as a going concern.                                                          |

| ● | Our limited operating history makes it difficult to evaluate our business 
 and future prospects.                                                     |

| ● | We are unable to precisely estimate when we will begin to generate significant 
 profit from PPLS.                                                              |

| ● | We have limited experience operating a laboratory. |

Risks Related to this Offering

| ● | Resales of our Common Stock in the public market                                     
 as a result of this offering may cause the market price of our Common Stock to fall. |

| ● | Investors who buy shares at different times will 
 likely pay different prices.                     |

| ● | This offering may cause the trading price of 
 our Common Stock to decrease.                |

| ● | Our management will have broad discretion over 
 the use of the net proceeds.                   |

Risks Related to our Diagnostic Product

| ● | The FDA could impose greater regulatory burdens on laboratory developed tests 
 (“LDTs”).                                                                     |

| ● | Delays or difficulties in the enrollment of patients could delay or prevent 
 regulatory approvals